MGX vs. FENC, GLUE, PSTX, STRO, CHRS, AGEN, ADAP, IVVD, CADL, and OPT
Should you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Fennec Pharmaceuticals (FENC), Monte Rosa Therapeutics (GLUE), Poseida Therapeutics (PSTX), Sutro Biopharma (STRO), Coherus BioSciences (CHRS), Agenus (AGEN), Adaptimmune Therapeutics (ADAP), Invivyd (IVVD), Candel Therapeutics (CADL), and Opthea (OPT). These companies are all part of the "biological products, except diagnostic" industry.
Fennec Pharmaceuticals (NASDAQ:FENC) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, valuation, profitability, dividends, risk, media sentiment and institutional ownership.
Fennec Pharmaceuticals currently has a consensus price target of $17.33, indicating a potential upside of 77.78%. Metagenomi has a consensus price target of $17.83, indicating a potential upside of 172.26%. Given Fennec Pharmaceuticals' higher possible upside, analysts clearly believe Metagenomi is more favorable than Fennec Pharmaceuticals.
Fennec Pharmaceuticals received 182 more outperform votes than Metagenomi when rated by MarketBeat users. However, 88.89% of users gave Metagenomi an outperform vote while only 65.29% of users gave Fennec Pharmaceuticals an outperform vote.
Metagenomi has a net margin of 0.00% compared to Metagenomi's net margin of -75.50%.
In the previous week, Metagenomi had 4 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 10 mentions for Metagenomi and 6 mentions for Fennec Pharmaceuticals. Metagenomi's average media sentiment score of 0.95 beat Fennec Pharmaceuticals' score of 0.87 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media.
55.5% of Fennec Pharmaceuticals shares are held by institutional investors. 11.3% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Fennec Pharmaceuticals has higher earnings, but lower revenue than Metagenomi.
Summary
Fennec Pharmaceuticals and Metagenomi tied by winning 7 of the 14 factors compared between the two stocks.
Get Metagenomi News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Metagenomi Competitors List
Related Companies and Tools
